135 related articles for article (PubMed ID: 32769290)
1. Pediatric chronic myeloid leukemia with myeloid blast crisis and complex karyotype at presentation.
Sazawal S; Singh K; Chhikara S; Chaubey R; Mishra P; Seth T; Saxena R
Indian J Cancer; 2020; 57(3):343-345. PubMed ID: 32769290
[No Abstract] [Full Text] [Related]
2. The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis.
Eskazan AE
J Med Econ; 2018 Jul; 21(7):709-711. PubMed ID: 29673265
[No Abstract] [Full Text] [Related]
3. Acquisition of Inv(16)(p13q22) in a blast crisis of chronic myeloid leukemia: case report.
Oñate G; Blanco ML; Pratcorona M
Med Clin (Barc); 2019 May; 152(10):419-420. PubMed ID: 30392698
[No Abstract] [Full Text] [Related]
4. Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: a single-institution experience.
Moschovi M; Adamaki M; Athanasiadou A; Divane A; Karytianou A; Tourkantoni N
Leuk Lymphoma; 2015; 56(8):2460-2. PubMed ID: 25641431
[No Abstract] [Full Text] [Related]
5. The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
Asemissen AM; Dierlamm J
Blood; 2017 Sep; 130(10):1274. PubMed ID: 28882836
[No Abstract] [Full Text] [Related]
6. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
[TBL] [Abstract][Full Text] [Related]
7. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
Angriman F; Gutierrez Acevedo MN; Rossi MS; Gimenez Conca AD; Otero V; Arbelbide JA; Michelángelo H
Turk J Haematol; 2015 Jun; 32(2):193-4. PubMed ID: 26316496
[No Abstract] [Full Text] [Related]
8. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
9. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
Proschmann R; Baldow C; Rothe T; Suttorp M; Thiede C; Tauer JT; Müller MC; Hochhaus A; Roeder I; Glauche I
Haematologica; 2017 Feb; 102(2):e39-e42. PubMed ID: 27856510
[No Abstract] [Full Text] [Related]
10. Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia.
Al-Shehri A; Al-Seraihy A; Owaidah TM; Belgaumi AF
Hematol Oncol Stem Cell Ther; 2010; 3(1):42-6. PubMed ID: 20231813
[TBL] [Abstract][Full Text] [Related]
11. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
[No Abstract] [Full Text] [Related]
12. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
13. Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
Maschan A; Novichkova G; Miakova N; Persiantseva M
Pediatr Blood Cancer; 2016 Dec; 63(12):2243-2245. PubMed ID: 27434016
[TBL] [Abstract][Full Text] [Related]
14. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
15. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
[No Abstract] [Full Text] [Related]
16. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Wang W; Cortes JE; Liu E; Miranda RN; Zhao C; Yuan J; Lu X; Yang W; Ameri MD; Kantarjian HM; Medeiros LJ; Hu S
Blood Cancer J; 2016 May; 6(5):e418. PubMed ID: 27152845
[No Abstract] [Full Text] [Related]
17. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
Qing X; Qing A; Ji P; French SW; Mason H
Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
Liu NS; O'Brien S
Leuk Lymphoma; 2002 Dec; 43(12):2413-5. PubMed ID: 12613534
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
20. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
